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Abstract
 
Reactivation of telomerase and maintenance of telomere length can lead to the prevention of
replicative senescence in some human somatic cells grown in vitro. To investigate whether telo-
mere shortening might also play a role in the limitation of hematopoietic stem cell (HSC) divi-
sion capacity in vivo, we analyzed telomere length during serial transplantation of murine
HSCs. Southern blot analysis of telomere length in donor bone marrow cells revealed extensive
shortening (
 
z
 
7 kb) after just two rounds of HSC transplantation. The number of cycling HSCs
increased after transplantation and remained elevated for at least 4 mo, while the frequency of
HSCs in the bone marrow was completely regenerated by 2 mo after transplantation. Direct
analysis of telomeres in HSCs by fluorescent in situ hybridization during serial transplantation
also revealed a reduction in telomere size. Together, these data show that telomeres shorten
during division of HSCs in vivo
 
,
 
 and are consistent with the hypothesis that telomere shorten-
ing may limit the replicative capacity of HSCs.
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Introduction
 
The cellular components of many, if not all, tissues of
higher eukaryotes are derived and maintained by stem
cells, which are capable of both self-renewal and commit-
ted differentiation into one or more lineage subsets. He-
 
matopoietic stem cells (HSCs),
 
1
 
 which can give rise to all
cells of the hematopoietic lineage, can be identified and
purified on the basis of cell surface phenotype (1, 2). Mu-
rine long-term HSCs reside in the bone marrow at a rare
 
frequency of 
 
z
 
1 in 10,000, where they slowly and contin-
uously turn over to supply cells for the hematopoietic sys-
tem throughout the life span of the animal (3–5).
Early work by Hayflick and Moorhead showed that cul-
tured human diploid fibroblasts have a finite replicative ca-
pacity and eventually undergo senescence (6). In subse-
quent studies, many other somatic cell types in humans and
other organisms were found to have a finite replicative ca-
pacity (for a review, see reference 7). Although replicative
senescence has not been as well characterized in mice as in
humans, serial bone marrow transplantation experiments in
mice by Harrison and Astle provide strong evidence that
HSCs also have a limited capacity to divide in vivo
 
 
 
(8).
Telomeres are the genetic elements capping the ends of
chromosomes, and serve to guard against degradation and
spurious end to end fusions (9, 10). In vertebrates, the se-
quence of telomeric DNA is (TTAGGG)n (11). Telomeres
can be relatively long in inbred mice, 
 
mus musculus
 
, ranging
from 20 to 100 kb or more (12–15), compared with 3–12
kb in humans (16–18). Telomerase, a ribonucleoprotein
complex, functions to complete the replication of telo-
meres during S phase by synthesis of single-stranded telo-
meric DNA onto the 3
 
9
 
 overhang at the telomeric termi-
nus (19). Telomerase activity is present in human germ line
cells and tumor cells (20, 21), but is absent or present at
very low levels in most human somatic cells (21, 22). Con-
sequently, telomeres gradually shorten during division of
the latter cells, but not the former (17, 22, 23). Hypotheses
have been proposed which predict that the shortening of
telomeres during replicative aging of human somatic cells
may cause cell senescence (24, 25). Recently, it has been
shown that overexpression of terminal reverse transcriptase,
the catalytic component of telomerase (26), in human so-
matic cells grown in vitro allows regeneration of telomere
length and immortalization of these cells (27).
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Abbreviations used in this paper:
 
 FIGE, field inversion gel electrophore-
sis; FISH, fluorescent in situ hybridization; HSC, hematopoietic stem cell;
PNA, peptide nucleic acid; TRF, terminal restriction fragment. 
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Telomeres also shorten in human hematopoietic cells
during replicative aging in vitro (28), and in vivo (18, 29,
30), and accelerated telomere shortening has been reported
in the bone marrow of transplant recipients (31). These ob-
servations imply that telomeres also shorten during division
of HSCs, although this has not been thoroughly estab-
lished. HSCs also express high levels of telomerase com-
pared with other hematopoietic cells (32). Thus, the rele-
vance of telomere shortening to the finite replicative
capacity of HSCs in vivo is not yet clear. To investigate this
issue, we have now analyzed the effect of serial transplanta-
tion of HSCs in mice on telomere length and cell cycle sta-
tus of HSCs.
 
Materials and Methods
 
Mice.
 
For all transplantation experiments, the C57Bl/Ka-
Thy1.1 (Ly5.1) strain (BA strain) was used as HSC donors and the
congenic C57Bl/Ka-Thy1.2 (Ly5.2) strain was used as recipients.
The initial donor mice and all the recipient mice were 2–3 mo
old. All mice were bred and maintained on acidified water (pH
2.5).
 
Antibodies.
 
The antibodies used in the immunofluorescence
staining included E13 (anti–Sca-1, Ly6A/E), C311.1 (anti–c-kit),
2B8 (anti–c-kit), 19XE5 (anti-Thy1.1), Al1-4A2 (Ly5.2), and
A20.1(anti-Ly5.1). Lineage marker antibodies included M1/70
(anti–Mac-1), GK1.5 (anti-CD4), KT31.1 (anti-CD3), 53-7.3
(anti-CD5), 53-6.7 (anti-CD8), Ter119 (anti–erythrocyte-spe-
cific antigen), 6B2 (anti-B220), and 8C5 (anti–Gr-1).
 
Bone Marrow Isolation and Immunostaining.
 
Bone marrow cells
were isolated and stained with fluorophor-conjugated antibodies
as described previously (4). In brief, marrow was aspirated from
the tibia and femur bones using staining media (HBSS plus 3% fe-
tal bovine serum, pH 7.2). For HSC analysis or isolation, cells
were resuspended in an antibody cocktail (CD3, CD4, CD5,
CD8, Ly5.2, Ter119, B220, Mac-1, and Gr-1, all PE-conjugated,
Sca-1
 
TR
 
, c-kit [2B8]
 
APC
 
, and Thy1.1
 
FITC
 
) and incubated on ice
for 30–40 min. Cells were then washed once and resuspended in
staining media containing 0.5 
 
m
 
g/ml propidium iodide. Cells
were maintained on ice at all times.
 
Flow Cytometric Analysis and Sorting of HSCs.
 
For isolation of
HSC by FACS
 
®
 
, bone marrow cells were first stained with c-kit
(C311.1)
 
bio
 
 and then enriched by positive selection using MACS
(Miltenyi Biotec) streptavidin-conjugated magnetic beads, ac-
cording to the manufacturer’s instructions. The enriched cells
were stained with the antibody cocktail described above. HSCs
are defined as the c-kit
 
1
 
Sca-1
 
1
 
Thy1.1
 
lo
 
Lin
 
2
 
 population and can
be purified to
 
 .
 
95% by double sorting. All analyses and cell sort-
ing were performed on a dual-laser FACS Vantage™ machine
(Becton Dickinson).
 
Cell Cycle Analysis of HSCs.
 
Bone marrow cells were simul-
taneously stained with antibodies for HSC detection and with
Hoechst 34332 dye followed by FACS
 
®
 
 analyses of the percent-
age of HSCs in the S/G2/M phase of the cell cycle as described
previously (5).
 
DNA Isolation and Terminal Restriction Fragment Length Analysis
by Field Inversion Gel Electrophoresis.
 
Bone marrow cells were
harvested at the time of the initial transplantation and 4 mo or
more following each subsequent round of transplantation. Cells
were resuspended in lysis buffer (10 mM Tris, 100 mM EDTA,
0.5% SDS, pH 8.0) containing 0.2 mg/ml proteinase K and incu-
 
bated overnight at 50
 
8
 
C. Cell lysates were extracted one to two
times with phenol/chloroform/isoamyl alcohol (25:24:1) and
once with chloroform. The DNA was ethanol precipitated, and
the pellet was washed once with ethanol and resuspended in Tris-
EDTA buffer. To obtain DNA that runs clean during field inver-
sion gel electrophoresis (FIGE), each sample was further extracted
with DNAzol (GIBCO BRL) according to the manufacturer’s
instructions and once more resuspended in TE buffer. DNA in-
tegrity was assessed by ethidium bromide staining following aga-
rose gel electrophoresis and by Southern blot analysis of the uncut
DNA using a telomeric probe as described (23, 29). For each
sample, DNA was digested to completion with the restriction en-
zymes HinfI, RsaI, HhaI, and HpaII. The digested DNA samples
(1–0.5 
 
m
 
g) were then resolved in 0.75% agarose gels using FIGE
(pulse conditions: 0.8 V forward; 0.4 V reverse for 12 h). The
gels were then dried down and terminal restriction fragments
(TRFs) were detected by hybridization to a 
 
32
 
P-end labeled telo-
meric oligomer as described previously (23, 29).
 
Fluorescent In Situ Hybridization.
 
1,000 HSCs were double
sorted into staining media and cytospun (500 rpm for 5 min) onto
glass slides. The slides were air dried and the cells were fixed to
the slides by immersion in a 4% paraformaldehyde/PBS solution
for 5 min at room temperature. The slides were then air dried
overnight before performing fluorescent in situ hybridization
(FISH). Telomeres were stained with an FITC-conjugated pep-
tide nucleic acid (PNA) telomeric oligomer, (CCCTAA)3 (Ap-
plied Biosystems) using the FISH protocol developed by Lans-
dorp and coworkers (33). Images were collected and quantitative
analysis of the fluorescent signal intensity was performed using a
ZEISS confocal microscope. Control slides of unstained cells
were used to correct for background fluorescence.
 
Results
 
Telomeres Are 
 
,
 
50 kb in Size for Hematopoietic Cells from
Some mus musculus Strains.
 
FIGE allows high resolution of
DNA fragments in the size range of 5–200 kb (34). Since
the previously reported size of TRFs in 
 
mus musculus 
 
is
within this range (12–15), we used FIGE to perform
Southern blot analysis of TRF length for DNA samples
from mouse hematopoietic cells. A typical Southern blot
analysis showing the range in TRF sizes for bone marrow
cells and splenocytes from four different mouse strains is
shown in Fig. 1. For all strains, the TRFs are predomi-
nantly in the size range of 10–50 kb. The TRF size range
for the C57Bl/Ka-Thy1.1 (BA) strain, the donor strain
used for serial HSC transplantation, is 
 
z
 
10–40 kb, some-
what less than the TRF size range for early passage mouse
embryonic fibroblasts established from the same strain
(
 
z
 
30–50 kb; Fig. 1).
 
An Increase in Frequency of Cycling HSCs Accompanies Res-
toration of the Donor HSC Pool after Transplantation.
 
Long-
term HSCs divide slowly and continuously (8% per day) in
the bone marrow of adult BA mice (5), with 5% of the
HSC pool in the S/G2/M phase of the cell cycle at any
given time (4, 5). After transplantation into irradiated hosts,
virtually all bone marrow and splenic HSCs initially enter
the cell cycle. However, little is known regarding the long-
term cycling activity of the transplanted HSC pool during
hematopoietic reconstitution in recipient mice. Also, the 
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kinetics and extent of restoration of the donor HSC pool,
as assessed directly by surface phenotype analysis, during
serial transplantation have not been well characterized.
Therefore, bone marrow cells from BA mice and HSC
transplant recipient mice were stained simultaneously for
HSC detection and with Hoechst dye to determine the fre-
quency of HSCs and the fraction of HSCs in the S/G2/M
phase of the cell cycle (Fig. 2 A). 4 wk after transplant, a
significant increase in the number of HSCs in the S/G2/M
phase of the cell cycle was observed for recipient mice re-
constituted with bone marrow containing either 30 HSCs
(
 
P 
 
= 0.0005) or 3,000 HSCs (
 
P 
 
= 0.003; Fig. 2 B). Re-
 
markably, even 4 mo after the transplant, the frequency of
HSCs in the S/G2/M phase of the cell cycle was still signif-
icantly elevated for both recipients of bone marrow con-
taining 30 HSCs (
 
P 
 
= 0.02) or 3,000 HSCs (
 
P 
 
= 0.05; Fig.
2 B).
 
 
 
We also observed, for both primary and secondary re-
cipients reconstituted with 100–200 donor HSCs, a resto-
ration of the donor HSC pool to levels normally found in
young adult BA mice (
 
z
 
0.02%; Table I) by 2 mo after
transplant. However, there was a marginal decrease in the
total number of donor HSCs after each round of transplan-
tation reflected in a drop in frequency of donor cells in the
recipient mice after each round of transplantation (Table I).
The reason for this slight drop in donor cell frequency is
not clear. We believe that it may be accounted for in part
by the increased cell cycle activity of the transplanted
HSCs, since our data suggest that engrafted HSCs do not
quickly return to the low levels of turnover observed for
untransplanted HSCs (Fig. 2), and we have established pre-
viously that in various conditions, S/G2/M phase HSCs
engraft after transplantation less well than G0/G1 HSCs
(see Discussion, and references 35, 36). It is also possible
that a small proportion of the transplanted HSCs may either
die, for reasons other than poor engraftment, or perhaps
exhaust their replicative capacity during hematopoietic re-
constitution in primary recipients and, to a greater extent,
in secondary recipients.
 
Size of TRFs from Donor Hematopoietic Cells Decreases dur-
ing Serial Transplantation of HSCs.
 
It is well established
that telomere length shortens in hematopoietic cells during
aging in humans and during expansion in vitro
 
 
 
(18, 28, 29).
To assess whether telomere shortening also accompanies
Figure 1. FIGE analysis of
TRF length for hematopoietic
cells from different mus musculus
strains. DNA was isolated from
bone marrow cells (BM) and
splenocytes (SP) from young
adult mice, as well as murine em-
bryonic fibroblasts (MEF) estab-
lished from the BA strain, and
digested with the restriction en-
zymes as described (see Materi-
als and Methods). 1 mg of each
DNA sample was resolved in a
0.75% agarose gel by FIGE (pulse
conditions, 0.8 V forward and 0.4
V reverse for 12 h). The gel was
dried and the DNA hybridized to
a 32P-end labeled telomeric oligo-
mer as described (see Materials
and Methods). Sizes of molecular
weight standards (in kb) are
shown on the left.
Figure 2. Analysis of cell cycle status of HSCs after
transplantation. (A) Detection of HSCs in the S/G2/M
phase of the cell cycle by FACS® analysis. Bone marrow
was isolated from adult BA mice and primary recipients (1
mo after transplant) and immunostained for HSC detection
with Hoechst dye (see Materials and Methods). Shown are
sample side scatter (y-axis) and Hoechst fluorescence (x-
axis) density plots of HSCs (Sca11c-kit1Lin2Thy1.1lo cells)
from a typical adult BA mouse (top) and a primary recipi-
ent reconstituted with 3 3 105 bone marrow cells (z30
HSCs) (bottom). Boxes indicate the subpopulation of
HSCs in the S/G2/M phase of the cell cycle, showing the
percentage of S/G2/M phase HSCs. (B) Analysis of the
frequency of cycling HSCs. The average relative frequency
of HSCs in S/G2/M for adult BA mice and primary recip-
ients reconstituted with z3 3 105 or z3 3 107 bone mar-
row cells (30 and 3,000 HSCs, respectively) is shown at
4 wk after transplant (top) and 4 mo after transplant (bot-
tom). Error bars (standard deviation) and P value (Student’s
t test) are shown. 
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the increased replicative demand on HSCs after transplan-
tation, we serially transplanted either whole bone marrow
cell populations containing 100-200 HSCs or 100-200
pure HSCs isolated by FACS
 
®
 
. Subsequently, FIGE was
used to analyze the TRF length of bone marrow cells from
young adult BA mice, primary recipients, and secondary
recipients. To ensure that all donor cells in the recipient
mice were derived from the donor HSC population, we
performed the TRF length analysis at 4 mo or more after
transplantation since only the donor HSC population is ca-
pable of maintaining donor-derived hematopoietic cell lev-
els for this duration (4). All transplant recipient mice used
for telomere length analysis had a donor hematopoietic cell
frequency of 80% or greater (data not shown).
As shown in Fig. 3 A, a substantial reduction in TRF
length after each round of transplantation is observed. No-
tably, the range in TRF length for donor-derived bone
marrow cells from secondary recipients was just
 
 z
 
7–23 kb,
comparable to the TRF size range for human germ line or
 
fetal cells (16, 23, 30). The mean TRF length was also cal-
culated and averaged for all experiments (Fig. 3 B). We ob-
served a significant decrease in mean TRF length after each
round of transplantation (Fig. 3 B). After just two rounds of
HSC transplantation, the telomere length had decreased by
 
z
 
7 kb. Similar results were observed after FIGE analysis
of TRF length for donor-derived splenocytes (data not
shown). The hematopoietic profile of the donor marrow
cells, as assessed by analysis of the frequency of various he-
matopoietic lineages, was not altered during serial trans-
plantation (data not shown).
To assess whether the extent of reduction in telomere
length was dependent on the initial dose of transplanted
HSCs, we compared the mean TRF length for primary re-
cipients reconstituted with either 30 or 3,000 HSCs. At 4
mo after transplant, mice (
 
n 
 
= 7) reconstituted with 30
HSCs had significantly shorter telomeres (21.7 kb) than
mice (
 
n 
 
= 6) reconstituted with 3,000 HSCs (22.7 kb; 
 
P 
 
=
0.04).
 
Fluorescent Telomeric Signal Intensity Decreases in HSCs dur-
ing Serial Transplantation.
 
We used FISH rather than
FIGE to assess telomere length directly in HSCs during se-
rial transplantation because of the scarcity of these cells.
1,000 HSCs were isolated by FACS
 
®
 
 from two adult BA
mice and secondary recipients, cytospun onto glass slides,
and stained by hybridization to an FITC-conjugated PNA
telomeric oligomer (33). There is a general decrease in
telomeric signal intensity for individual HSC nuclei from
secondary recipients compared with HSC nuclei from adult
BA mice (Fig. 4 A). Quantitative analysis of the telomeric
signal intensity for individual HSC nuclei using a confocal
microscope revealed a significant reduction in telomere
length (
 
z
 
30%; 
 
P 
 
= 0.001) for HSCs after two rounds of
transplantation (Fig. 4 B). This reduction in telomeric
signal intensity during serial HSC transplantation agrees
reasonably well with the reduction in TRF length for do-
nor-derived bone marrow cells from secondary recipients
assessed using FIGE (Fig. 3).
 
Table I.
 
Quantitation of HSCs during Serial Transplantation
 
Total WBCs
 
*
 
 Donor cells
 
‡
 
HSCs
 
§
 
Total HSCs
 
%%
 
BA 9.1 
 
3 
 
10
 
7
 
100 0.019 
 
6 
 
0.001 1.7 
 
3 
 
10
 
4
 
Primary
 
i
 
8.5 
 
3 
 
10
 
7
 
92 
 
6 
 
4 0.021 
 
6 
 
0.002 1.6
 
 3 
 
10
 
4
 
Secondary
 
i
 
8.4 
 
3 
 
107 81 
 
6 
 
5 0.020 
 
6 
 
0.002 1.4 
 
3 
 
10
 
4
 
*
 
The total WBCs from the two tibia and femur bones.
 
‡
 
Analysis was done 8 wk after transplantation. For all sets of mice, 
 
n
 
 = 6.
 
§
 
Taken as the percentage of the Ly5.1
 
1
 
 marrow population.
 
i
 
Both primary and secondary recipients were reconstituted with either
100–200 HSCs isolated by FACS
 
®
 
 or bone marrow aliquots containing
100–200 HSCs. For the secondary transplant, primary recipients at
4 mo or more after transplant were used as donors.
Figure 3. FIGE analysis of TRF length of bone mar-
row cells during serial HSC transplantation. (A) South-
ern blot analysis of TRF length by FIGE. In this sample
analysis, all primary recipients and two secondary re-
cipients, represented by the rightmost two lanes, were
reconstituted with 100 pure HSCs. The other two sec-
ondary recipients were reconstituted with 2 3 106
bone marrow cells. Whole bone marrow cells were
isolated from adult BA mice and recipient mice and di-
gested with restriction enzymes as described (see Mate-
rials and Methods). 0.5 mg of each digested DNA sam-
ple was resolved in a 0.75% agarose gel by FIGE (pulse
conditions, 0.8 V forward and 0.4 V reverse for 12 h).
The bone marrow sample of the donor mouse in each
round of transplantation is indicated by an arrow (¯) at
the top. The gel was dried and the DNA hybridized to
a 32P-end labeled telomeric oligomer as described (see
Materials and Methods, and reference 23). Sizes of mo-
lecular weight standards (in kb) are shown on the left.
(B) Measurement of mean TRF length during serial
transplantation. The mean TRF length was calculated as described previously (references 23, 29) for a total of 9 sibling adult BA mice, 11 primary recip-
ients, and 10 secondary recipients and averaged for all experiments. Error bars (standard deviation) and P values (Student’s t test) are shown. 
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Discussion
This study investigates the potential role of telomere
shortening on the finite in vivo replicative capacity of
HSCs during transplantation. We show that telomere
length in mus musculus hematopoietic cells is relatively short
and can be readily measured by FIGE. HSCs were found to
be more frequently in cycle for several months after trans-
plantation and the relative abundance of HSCs is restored
to normal levels after one or two rounds of serial transplan-
tation. We also show that telomeres shorten extensively in
most, if not all, donor hematopoietic cells, including HSCs,
during serial HSC transplantation.
Our analysis of telomere length in BA mice (C57Bl/Ka-
Thy1.1 mice), the donor strain used for HSC transplanta-
tion, as well the related C57Bl/6J mice, shows that the
TRFs for these strains range in size from z10 to 40 kb
(Figs. 1 and 3). While this is a substantially lower size range
for TRFs than what has generally been reported for other
inbred mice strains (12–14), studies that have directly as-
sessed TRF length in the C57Bl/6J mice have also found
that the TRF size range for these mice (z20–75 kb; 12, 13,
15) is less than the size of TRFs from other inbred strains.
In addition, considerable variation in telomere length
among different inbred strains (12, 13, 15), different lab
colonies (13), and even individual mice of the same mouse
strain (13) has also been shown to occur. Thus, the results
from our analysis of TRF length in mice agree reasonably
well with what has been published previously.
As might be predicted, the number of cycling HSCs did
increase during hematopoietic reconstitution of the trans-
plant recipients, and was inversely proportional to the ini-
tial number of transplanted HSCs (Fig. 2). Surprisingly, the
cycling activity of the donor HSCs remained elevated for at
least 4 mo after transplant. The myeloid and lymphoid lin-
eages were both reconstituted (data not shown) and the do-
nor HSC pool was restored to normal levels within the first
8 wk after transplantation (Table I); thus, the reason for this
sustained cycling activity of the donor HSC pool is not
clear. It may reflect a long-term stress response of the ani-
mal to a lethal dose of irradiation, long-term impairment of
immune protection during hematopoietic reconstitution,
and/or a slightly reduced ability of the donor-derived he-
matopoietic cells to thrive in a foreign host.
After two rounds of serial transplantation, the frequency
of donor HSCs showed little change from that observed in
young adult BA mice (Table I). However, evidence for a
decrease in HSC concentration after bone marrow trans-
plantation has been reported in earlier studies, in which
HSC concentration was calculated by either limit dilution
analysis (37) or analysis of covariance in recipients of mix-
tures of whole bone marrow from two genetically distin-
guishable donor strains (38). Although the reason for this
discrepancy is unknown, it is likely accounted for in part by
differences in methodology. The transplantations in these
earlier studies included competitor cells and determined
donor HSC frequency relative to the total number of mar-
row cells in the recipient mice, whereas our transplants
were done without competition and donor HSC frequency
calculations were performed relative to the donor marrow
population. Also, the methods used to determine HSC
number in these earlier studies are based on functional as-
says, unlike our method of direct analysis of HSCs based on
cell surface phenotype, and therefore cannot clearly distin-
guish between a decline in functional retransplantation
ability of HSCs and actual HSC number.
Telomere length analysis of donor-derived bone marrow
cells (Fig. 3) and HSCs (Fig. 4) shows substantial telomere
shortening during serial HSC transplantation. The differ-
ence in mean TRF length (DTRF) of bone marrow cells
after one round of HSC transplantation is z1.5 kb (Fig. 3
Figure 4. FISH analysis of telomere length of HSCs from adult BA
mice and secondary recipients. (A) Confocal microscope image of individ-
ual HSC nuclei after hybridization to a fluorescent telomeric probe. 1,000
HSCs were isolated from the pooled bone marrow from two BA mice and
two secondary recipients by FACS®, cytospun onto glass slides, and fixed
as described (see Materials and Methods). The telomeres were detected by
FISH using an FITC-conjugated PNA telomeric oligomer as described by
Lansdorp et al. (reference 33). Individual interphase nuclei are indicated
by arrowheads. Image was collected using a 603 objective. The size scale
(in mm) is indicated in the lower left. (B) Fluorescent signal intensity mea-
surements of HSC nuclei. After FISH, the fluorescent telomeric signal in-
tensity was calculated and corrected for background for 30 well-isolated
individual HSC nuclei from both adult BA mice and secondary recipients.
The mean fluorescent signal intensity and corresponding standard devia-
tion are shown. P value was calculated by Student’s t test.922 Telomere Shortening in Cycling HSCs during Serial Transplantation
B). This agrees reasonably well with the predicted reduc-
tion in telomere size assuming that DTRF is mainly due to
the minimum number of extra population doublings
(z12–13) required for expansion of the fraction of the
transplanted HSC population which engraft to the size of
the HSC pool in adult mice (z3–5 3 104 cells; references
3, 4), and that the rate of telomere shortening during divi-
sion of the transplanted HSCs is 50–100 bp per population
doubling, as observed for other mouse cells (14, 39, 40).
However, the extent of telomere shortening during the
second round of HSC transplantation (DTRF ø 5.5 kb) is
considerably greater than DTRF during the first round of
transplantation (Fig. 3). One possible explanation for this is
that the intrinsic properties of the donor HSC population
may have changed, after the second transplantation, to ef-
fect an increase, by whatever mechanism(s), in the rate of
telomere shortening. However, we favor a model, as out-
lined in Fig. 5, in which the increase in DTRF is primarily
accounted for by an increase in the rate of HSC turnover
during self-renewal and/or hematopoietic reconstitution.
This notion is supported by the following observations. (a)
Telomere shortening is mainly, if not entirely, dependent
on cell division. Telomere shortening has only been ob-
served in dividing cell populations or tissues, and direct
comparison of changes in telomere length over time in ac-
tively replicating cells and very slowly replicating cells re-
veals telomere shortening in the former, but little or no
shortening in the latter (41). (b) We find that the telomere
length in the recipient bone marrow is shorter in mice re-
constituted with 100 times fewer HSCs (see Results),
which further supports a mechanism involving increased
cell division. (c) The frequency of cycling HSCs increases
in response to transplantation (Fig. 2), as well as several
stressors including cytoxan/G-CSF–induced HSC mobili-
zation (42) and the aging process (43), and the reconstitu-
tive capacity of HSCs is inversely correlated with the cycling
activity (35, 36, 42, 43). Direct transplantation of S/G2/M
HSCs demonstrated that these cycling HSCs engraft quan-
titatively less well than G0/G1 HSCs (36), although they
retain multipotent hematopoietic activity at the single cell
level (42, 43). The reason for this behavior is unknown,
but may possibly reflect a reduced ability of cycling HSCs
to home to and settle in the bone marrow, the only site of
large-scale hematopoiesis. Another possible explanation for
the increased telomere shortening during the second round
of transplantation is a reduction in telomerase activity in
HSCs during transplantation, which in turn could lead to
an accelerated rate of telomere loss. This possibility is ame-
nable to testing.
The precipitous drop in telomere length that we observe
during serial transplantation of HSCs in mice is consistent
with the shortening of telomeres that others have observed
in the donor cells from bone marrow transplant recipients
(31), and in candidate HSCs during aging in humans (30).
It will be important to test whether telomere shortening or
other events, such as the increase in cell cycle activity in re-
sponse to transplantation, ultimately limits the replicative
life span of HSCs during serial transplantation. To test these
nonexclusive possibilities, it will be important to carry out
serial transplantation of HSCs to exhaustion in mice to de-
termine if the telomere length becomes critically short.
Also, it will be informative to test transgenic mice that
overexpress murine terminal reverse transcriptase in HSCs
to assess whether telomere length is maintained in these
mice and what effect this has on the long-term transplanta-
tion capacity of HSCs.
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cell division (reference 41), there is no discernible telomere shortening
over a time period of a few months in adult BA mice (data not shown).
After transplantation into primary recipients, the cycling activity of the
donor HSCs increases (thicker arrows), primarily to allow reconstitution
of all hematopoietic lineages including the HSC pool. Consequently, a
modest amount of telomere shortening occurs. The cycling activity of
the donor HSCs is still elevated when they are once again isolated for a
second round of transplantation. This results in a considerable drop in re-
constitutive capacity because of poor engraftment in the secondary recip-
ients and a further increase in the rate of HSC turnover (thickest arrows)
so that regeneration of the HSC pool and hematopoietic reconstitution
can be completed once again. It is also possible that, after transplantation,
HSCs from primary recipients may be more prone to cell death or repli-
cative exhaustion than HSCs taken directly from adult mice, which
could also influence the rate of HSC division in secondary recipients.
Thus, during hematopoietic reconstitution in the secondary recipients,
telomeres in the HSCs undergo an even greater degree of shortening.923 Allsopp et al.
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